Učitavanje...
Drug–drug interactions during antiviral therapy for chronic hepatitis C
The emergence of direct-acting antiviral agents (DAAs) for HCV infection represents a major advance in treatment. The NS3 protease inhibitors, boceprevir and telaprevir, were the first DAAs to receive regulatory approval. When combined with PEG-IFN and ribavirin, these agents increase rates of susta...
Spremljeno u:
| Izdano u: | Nat Rev Gastroenterol Hepatol |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2013
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4634866/ https://ncbi.nlm.nih.gov/pubmed/23817323 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrgastro.2013.106 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|